Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.
Cancer medicine
View this publicationMember, Steering-Committee Member
Medical Faculty, University of Bonn University Hospital of Bonn Venusberg-Campus 1 53127 Bonn
Our mission is to improve the treatment and prolong the survival of cancer patients. Using preclinical cancer models and patient-derived material we aim to decipher the complex interactions between immune cells and cancer cells to identify novel druggable targets. Our current research focuses on understanding the importance of activating receptors in anti-cancer immune responses.
Cancer medicine
View this publicationNature immunology
View this publicationNature immunology
View this publication